Skip to content

BridgeBio Pharma BBIO Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin95.8%-2.4pp98.3%+24.5pp73.7%-21.9pp95.6%-0.5pp
Operating margin-104.2%+163pp-267.2%+6,262pp-6,528.8%-5,869pp-659.6%+167pp
Net margin-146%+98.9pp-244.9%+6,777pp-7,021.9%-6,398pp-624.2%+217pp
Efficiency
Asset turnover0.5×+0.2×0.3×+0.3×-0.1×0.1×0.0×
Liquidity
Current ratio2.8×-1.9×4.7×+1.3×3.3×-1.2×4.5×-2.1×
Per Share
Book value per share-$10.89-38.1%-$7.89+5.2%-$8.32+2.2%-$8.51-41.1%
Valuation
Market capitalization$14.74B+184%$5.19B-26.2%$7.02B+517%$1.14B-53.6%
Price / sales29.4×+6.0×23.4×-732×754.9×+740×14.7×-20.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are BridgeBio Pharma's profit margins?
BridgeBio Pharma (BBIO) runs a 95.1% gross margin and a -90.5% operating margin, with a -125.9% net margin.
Where do BridgeBio Pharma's ratios come from?
Every ratio is computed from BridgeBio Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.